- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02022280
Effect of Proton Pump Inhibitors on Endothelial Function (PPI)
August 19, 2022 updated by: Stanford University
Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA.
In this randomized controlled crossover study, the investigators propose to test the hypothesis that proton pump inhibitors (PPIs) increase plasma levels of asymmetric dimethylarginine (ADMA), which is a marker of endothelial dysfunction.
The authors propose to evaluate ADMA concentrations and vascular function analysis in healthy volunteers and adults with a history of cardiovascular disease given PPI vs placebo for four weeks each.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female volunteers aged 18 to 75 years (n=10) or male or female volunteers with a history of coronary or peripheral artery disease (n=10)
- Able to understand the nature of the study and to give written informed consent
- Able to communicate well with the investigator himself or his/her representatives
- Body Mass Index between 18 kg/m^2 and 35 kg/m^2 at the screening visit
- Creatinine <1.5, and liver enzymes <2x normal, with all laboratory tests considered normal or of no significant clinical relevance to the study by the investigator
Exclusion Criteria:
- Contra-indication to proton pump inhibitor treatment
- Current treatment with PPI or H2 antagonist, and not able to tolerate withdrawal or washout of medication.
- Current or historical evidence of clinically severe cardiovascular, neurological, hematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolic or psychiatric disease.
- Any other acute or chronic disease which could influence the volunteer's health and/or the study results
- Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or hernia repair
- Use of enzyme inducers or enzyme inhibitor drugs within the last three months before the first drug administration
- Participation in another ongoing clinical trial
- Past or current drug exposure amounting to drug abuse or addiction
- Past or current alcohol exposure amounting to alcohol abuse or addiction (i.e. > 28 units per week for males, where 1 unit = one measure of spirit (25 mL), one glass of wine (125 mL) or 1/2 pint beer)
- Donation of blood or any other major blood loss (>500 mL) within three months before the study
- Unwilling or unable to comply with the study protocol for any reason or in the opinion of the investigator should not participate in the study
- Positive test for hepatitis B surface antigen, hepatitis C antibody, HIV-1 or HIV-2 antibody at screening
- Known allergy or intolerance to any other compound in the study drug or any other closely related compound
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Proton Pump Inhibitor
Lansoprazole (Prevacid)
|
Other Names:
|
Placebo Comparator: Vitamin pill
|
Vitamin pill
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in reactive hyperemia index as measured by peripheral arterial tonometry (EndoPAT)
Time Frame: Baseline, 1 week, 5 weeks, 7 weeks, 11 weeks, 12 weeks
|
Baseline, 1 week, 5 weeks, 7 weeks, 11 weeks, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in blood ADMA level
Time Frame: Baseline, 1 week, 5 weeks, 7 weeks, 11 weeks, 12 weeks
|
Baseline, 1 week, 5 weeks, 7 weeks, 11 weeks, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nicholas Leeper, MD, Stanford University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2013
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
December 3, 2013
First Submitted That Met QC Criteria
December 20, 2013
First Posted (Estimate)
December 27, 2013
Study Record Updates
Last Update Posted (Actual)
August 23, 2022
Last Update Submitted That Met QC Criteria
August 19, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23848
- 1144447-121-DHAXB (Other Grant/Funding Number: Stanford Translational Research and Applied Medicine)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endothelial Dysfunction
-
M.D. Anderson Cancer CenterRecruitingEndothelial Dysfunction | Vascular | Endothelial | EndothelixUnited States
-
Clinica ARS MedicaUnknown
-
University of California, San DiegoCompletedEndothelial Dysfunction
-
M.D. Anderson Cancer CenterCompletedEndothelial DysfunctionUnited States
-
NestléCompleted
-
Société des Produits Nestlé (SPN)Completed
-
General Hospital of Chinese Armed Police ForcesChinese PLA General HospitalUnknown
-
University of ConnecticutCompletedEndothelial DysfunctionUnited States
-
Florida State UniversityRecruitingEndothelial DysfunctionUnited States
-
Poznan University of Physical EducationCompletedEndothelial DysfunctionPoland
Clinical Trials on Lansoprazole
-
Charles Mel Wilcox, MDTakeda Pharmaceuticals North America, Inc.CompletedZollinger-Ellison Syndrome | Multiple Endocrine Neoplasia
-
Vanderbilt UniversityTAP Pharmaceutical Products Inc.Completed
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingPeptic UlcerKorea, Republic of
-
Emory UniversityUnknown
-
Daewoong Pharmaceutical Co. LTD.UnknownHealed Erosive EsophagitisKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.Not yet recruitingPeptic UlcerKorea, Republic of
-
Onconic Therapeutics Inc.Not yet recruiting
-
Jordan Collaborating Cardiology GroupUniversity of JordanCompleted
-
University of UtahTerminated
-
University of Southern CaliforniaCompletedPeptic Ulcer HemorrhageUnited States